SCHEMBL29319722

SCHEMBL29319722

Cc1ccc(CCCC(=O)NCCC(C)C)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.76
PKM P14618 1/20 0.76
POLB P06746 2/20 0.64
HPGD P15428 3/20 0.55
KMT2A Q03164 2/20 0.50
PLAAT3 P53816 1/20 0.50
PLAAT5 Q96KN8 1/20 0.50
PLAAT2 Q9NWW9 1/20 0.50
PLAAT4 Q9UL19 1/20 0.50
HDAC3 O15379 2/20 0.49
HDAC4 P56524 2/20 0.49
HDAC1 Q13547 2/20 0.49
HDAC7 Q8WUI4 2/20 0.49
HDAC2 Q92769 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC8 Q9BY41 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
HDAC9 Q9UKV0 2/20 0.49
HDAC5 Q9UQL6 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27418517 0.87 LMNA (0.74) LMNAPKMPOLBHPGDKMT2A
SCHEMBL26179795 0.83 HPGD (0.58) LMNAPKMPOLBHPGDKMT2A
SCHEMBL23306964 0.83 LMNA (0.54) LMNAPKMPOLBHPGDKMT2A
SCHEMBL26707072 0.82 LMNA (0.67) LMNAPKMHPGDHDAC3HDAC4
SCHEMBL11236597 0.82 LMNA (0.67) LMNAPKMPOLBHPGDKMT2A
SCHEMBL22488362 0.82 ALB (0.54) LMNAPKMPOLBHPGDKMT2A
SCHEMBL24253210 0.82 ALB (0.57) LMNAPKMHPGDKMT2APLAAT3
SCHEMBL25730683 0.82 LMNA (0.53) LMNAPKMPOLBHPGDKMT2A
SCHEMBL10786159 0.82 LMNA (0.91) LMNAPKMHPGDKMT2AHDAC3
SCHEMBL21426817 0.82 HPGD (0.69) POLBHPGDKMT2APLAAT3PLAAT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238458-A1 COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF PURDUE RESEARCH FOUNDATION 2024-07-18 US disclosed
US-20240238458-A1 COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF PURDUE RESEARCH FOUNDATION 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238458-A1 COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF FAP, FIBP, FGFR1 LMNA 1909/4885PKM 3064/4885POLB 4230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.